FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Public ClinicalTrials.gov record NCT07446322. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Study identification
- NCT ID
- NCT07446322
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2026
- Primary completion
- Aug 29, 2027
- Completion
- Apr 29, 2030
- Last update posted
- Aug 25, 2026
2026 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Homewood | Alabama | 35209 | Recruiting |
| Clinical Research Advisors (Beverly Hills) | Beverly Hills | California | 90211 | Recruiting |
| Clinical Research Advisors (Encino) | Encino | California | 91316 | Recruiting |
| Clinical Research Advisors (Korea Town) | Koreatown | California | 90020 | Recruiting |
| Clinical Research Advisors (Downtown LA) | Los Angeles | California | 90033 | Recruiting |
| Clinical Research Advisors (West Hollywood) | Los Angeles | California | 90048 | Recruiting |
| Clinical Research Advisors (West Covina) | West Covina | California | 91790 | Recruiting |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30302 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46250 | Not yet recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Not yet recruiting |
| Summit Health Cancer Center | Florham Park | New Jersey | 07932 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Recruiting |
| Gabrail Cancer Center | Canton | Ohio | 44718 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07446322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07446322 live on ClinicalTrials.gov.